BioSpace News Archive

Galapagos NV announces a share capital increase arising from warrant exercises.

iTeos Therapeutics SA announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the upcoming Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3, 2019 at 10:50 a.m.

Neoleukin Therapeutics, Inc. “Neoleukin” announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the Piper Jaffray 31st Annual Healthcare Conference on Thursday, December 5, 2019 at 2:50 p.m. EST in New York.

CGuard™ EPS clinical data featured as a prominent discussion point in multiple key presentations

New research report estimates near-term market opportunity for emerging biosimilar markets, and examines role of drug delivery device design in competitive differentiation

Certain of Recipharm’s larger institutional shareholders, Första AP-fonden, Lannebo Fonder and Fjärde AP-fonden, support the cash offer for Consort Medical and have undertaken to fully support and vote in favour of a rights issue at a forthcoming general meeting of Recipharm and have also undertaken to subscribe for an amount corresponding to at least their respective pro rata share in a rights issue of SEK 2,000 million.

Marinomed Biotech AG has presented detailed data from its pivotal Phase III clinical trial for the therapeutic comparability of an aqueous solution of budesonide, a synthetic steroid for the treatment of hay fever.

BioLineRx Ltd., a clinical-stage biopharmaceutical company focused on oncology, announced that it will host an investor breakfast meeting on Thursday, December 5, 2019 at the Convene Conference Center near Grand Central Terminal in New York, N.Y.

BONE THERAPEUTICS informs its shareholders and holders of warrants and convertible bonds of the Company that an extraordinary general shareholder meeting will be held on Thursday 12 December 2019 at 10am CET, at the Company’s registered offices, rue Auguste Piccard 37, 6041 Gosselies, Belgium.

Agreement provides Enochian with exclusive rights to develop and commercialize a HBV treatment with a novel mechanism of action